Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC), a Delaware corporation, reporting an event dated September 6, 2023. The filing addresses a corporate action regarding the company's 6% Convertible Exchangeable Preferred Stock (CYCCP).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is the declaration of a quarterly cash dividend of $0.15 per share on the Preferred Stock.
Material Changes
The primary material event is the Board of Directors' declaration of a quarterly cash dividend. This dividend is payable on November 1, 2023, to holders of record as of the close of business on October 20, 2023.
Guidance, Outlook, and Risks
Management noted that the Board considered financial analysis and surplus determinations before declaring the dividend. The filing explicitly states there is no assurance that future quarterly dividends will be declared, as the Board will analyze the advisability of such declarations in future quarters.
Investor Verification Checklist
- Verify the record date of October 20, 2023, to confirm eligibility for the $0.15 per share dividend.
- Confirm the payment date of November 1, 2023, for the dividend distribution.
- Review the company's latest 10-Q or 10-K for underlying financial health, as this 8-K does not contain revenue or liquidity data.
- Monitor future filings for updates on the Board's decision regarding subsequent dividend declarations.